NVAX Novavax, Inc.
Debt Financing ·
About $49.7 million of the new convertible notes would be sold for cash, and about $175.3 million would be exchanged for 2027 notes. The exchange gives Novavax no cash. The company expects to close on or about August 27, 2025.
We have not published a story on Novavax yet. When there is news, it will appear here.
Novavax is a vaccine company whose technology platform combines its Matrix-M adjuvant with protein-based recombinant nanoparticle technology. The company says Matrix-M can induce a stronger and longer-lasting immune response when added to vaccines, and it provides the adjuvant for use in partner collaborations. Its authorized COVID-19 vaccine, Nuvaxovid, uses this platform. The R21/Matrix-M adjuvant malaria vaccine was developed by the Jenner Institute, University of Oxford, is manufactured by Serum Institute of India, and is authorized in several countries. Novavax's strategy is to maximize the impact of its technology by forging partnerships for its Matrix-M adjuvant and research and development assets while keeping a lean and focused operating model. The text says Matrix-M is used in various preclinical and clinical stage programs, including a pre-clinical collaboration in oncology. Novavax was incorporated in 1987 under Delaware law, and its common stock trades on the Nasdaq Global Select Market under the symbol NVAX.
| Product or program | What it is | Stage |
|---|---|---|
| Nuvaxovid | COVID-19 vaccine built on the Novavax technology platform | authorized |
| R21/Matrix-M™ adjuvant malaria vaccine | Malaria vaccine developed by Jenner Institute, manufactured by Serum Institute of India | authorized in several countries |
| Matrix-M | Adjuvant provided for vaccine collaborations and partner programs |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.12 billion | $682.2 million |
| Research and development | $342.3 million | $391.2 million |
| Net income (loss) | $440.3 million | -$187.5 million |
| Cash from operations | -$244.6 million | -$87.3 million |
| Cash and equivalents | $240.6 million | $530.2 million |
| Short-term investments | $494.4 million | $392.9 million |
Our latest story on this, dated Aug 21, 2025: "Novavax agrees to issue $225.0 million of 4.625% convertible senior notes due 2031". The story links the filing or release it is based on. Read the story.
Novavax, Inc. trades under the ticker NVAX on NASDAQ.
Novavax, Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:NVAX; BMV:NVAX; BSESOF:NVV1; BX:NVV1; DUS:NVV1; FWB:NVV1; GETTEX:NVV1; HAM:NVV1; HAN:NVV1; LS:A2PKMZ; LSIN:0A3S; LSX:A2PKMZ; MUN:NVV1; SWB:NVV1; TRADEGATE:NVV1; VIE:NVAX; XETR:NVV1.
The SEC Central Index Key (CIK) for Novavax, Inc. is 1000694. Its filings are on SEC EDGAR.
164,945,726 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Novavax, Inc. under United States.
Our directory classifies Novavax, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Novavax, Inc. is US6700024010.
aibio.space lists Novavax, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Novavax is a vaccine company whose technology platform combines its Matrix-M adjuvant with protein-based recombinant nanoparticle technology. The company says Matrix-M can induce a stronger and longer-lasting immune response when added to vaccines, and it provides the adjuvant for use in partner collaborations.
Nuvaxovid: COVID-19 vaccine built on the Novavax technology platform Stage: authorized.
R21/Matrix-M™ adjuvant malaria vaccine: Malaria vaccine developed by Jenner Institute, manufactured by Serum Institute of India Stage: authorized in several countries.
$1.12 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Novavax, Inc. reported net income of $440.3 million for the fiscal year ended Dec 31, 2025, and used $244.6 million of cash in operations, per its annual report to the SEC.
Reported a material impairment charge. SEC Form 8-K (Items 1.01,2.06,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio